Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model by Anna E. Kersh et al.
fphar-07-00327 September 22, 2016 Time: 16:0 # 1
REVIEW
published: 26 September 2016
doi: 10.3389/fphar.2016.00327
Edited by:
Rolando Pérez Rodríguez,
Centre of Molecular Immunology,
Cuba
Reviewed by:
Anna Rita Migliaccio,
Icahn School of Medicine at Mount
Sinai, USA
Paul B. Fisher,
Virginia Commonwealth University,
USA
*Correspondence:
Brian P. Pollack
brian.pollack@emory.edu
Specialty section:
This article was submitted to
Cancer Molecular Targets
and Therapeutics,
a section of the journal
Frontiers in Pharmacology
Received: 15 July 2016
Accepted: 06 September 2016
Published: 26 September 2016
Citation:
Kersh AE, Sasaki M, Cooper LA,
Kissick HT and Pollack BP (2016)
Understanding the Impact of ErbB
Activating Events and Signal
Transduction on Antigen Processing
and Presentation: MHC Expression as
a Model. Front. Pharmacol. 7:327.
doi: 10.3389/fphar.2016.00327
Understanding the Impact of ErbB
Activating Events and Signal
Transduction on Antigen Processing
and Presentation: MHC Expression
as a Model
Anna E. Kersh1, Maiko Sasaki2, Lee A. Cooper3,4, Haydn T. Kissick5 and
Brian P. Pollack2,6*
1 Medical Scientist Training Program, Emory University School of Medicine, Atlanta, GA, USA, 2 Atlanta VA Medical Center,
Decatur, GA, USA, 3 Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, USA,
4 Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA, 5 Department of Urology, Emory
University School of Medicine, Atlanta, GA, USA, 6 Department of Dermatology, Emory University School of Medicine,
Atlanta, GA, USA
Advances in molecular pathology have changed the landscape of oncology. The ability
to interrogate tissue samples for oncogene amplification, driver mutations, and other
molecular alterations provides clinicians with an enormous level of detail about their
patient’s cancer. In some cases, this information informs treatment decisions, especially
those related to targeted anti-cancer therapies. However, in terms of immune-based
therapies, it is less clear how to use such information. Likewise, despite studies
demonstrating the pivotal role of neoantigens in predicting responsiveness to immune
checkpoint blockade, it is not known if the expression of neoantigens impacts the
response to targeted therapies despite a growing recognition of their diverse effects
on immunity. To realize the promise of ‘personalized medicine’, it will be important to
develop a more integrated understanding of the relationships between oncogenic events
and processes governing anti-tumor immunity. One area of investigation to explore
such relationships centers on defining how ErbB/HER activation and signal transduction
influences antigen processing and presentation.
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INTRODUCTION AND OVERVIEW
Stated simply, oncogenic events are not immunologically null (Seliger, 2014). Defining the
immunologic impact of oncogenic events will be a critical area of research as advances in
molecular diagnostics parallel the expansion and availability of cancer immunotherapy (Whiteside
et al., 2016). Alterations in DNA sequence, copy number variation (CNV), transcriptional
profile, and epigenetics can all influence the expression of genes of the immune system,
immunologic processes, and ultimately anti-tumor immunity. The importance of antigen
processing and presentation in this regard is underscored by recent studies that have defined
the impact of mutation-derived neoantigens on the response to immune checkpoint blockade
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(Sorensen et al., 2009; van Rooij et al., 2013; Schumacher et al.,
2014; Snyder et al., 2014; Kelderman et al., 2015; Le et al., 2015;
Van Allen et al., 2015). These recent findings, further highlight
the importance of defining interactions between oncogenes,
oncogenic signal transduction, and the antigen processing
machinery (APM) (Seliger, 2014). Moreover, because the APM
plays a critical role in cancer immunoediting, understanding
how anti-cancer therapies (of all types) influence the APM will
be equally important (Galluzzi et al., 2012; Wargo et al., 2014;
Okwan-Duodu et al., 2015; Ward et al., 2016). The goal of this
article is to provide a framework for understanding interactions
between oncogenic ErbB/HER signal transduction and the APM,
using the expression of major histocompatibility complex (MHC)
molecules as a model.
Oncogenes and the APM – General
Considerations
Recent studies confirming the relevance of neoantigens, also
referred to as tumor specific antigens (TSA), provides enormous
rationale to understand how oncogenic events impact the
ability of tumor cells to process and present antigenic peptides.
Moreover, being able to pharmacologically manipulate the
expression of proteins that make up the APM takes on
additional relevance since defects within the APM are common
in human cancer and such alterations will likely influence the
peptide-MHC (pMHC) repertoires presented by tumors cells
(Seliger et al., 2000; Garrido et al., 2016). The dual ability of
ErbB/HER signaling to modulate large transcriptional programs
and influence MHC expression suggests that alterations in
the ErbB/HER family of ligands and/or receptors will change
the pMHC repertoire present at the surface of tumor cells.
Alterations of ErbB/HER receptors and ligands occurring in
human cancer are shown in Tables 1 and 2. This concept was
supported by the fact that ErbB/HER ligands and receptors
can greatly influence the cellular transcriptome, which in turn
influences the pMHC repertoire (Choi et al., 2007; Fortier et al.,
2008; Nagashima et al., 2008). In addition, the complex nature of
ErbB/HER signaling that results from having numerous ligands,
receptors, and mechanistically distinct activating events, supports
the idea that there will be differential effects on MHC expression.
While it will likely be cell-context dependent, defining ErbB/HER
oncogenic signaling in this manner provides an experimental
approach that can further our understanding of interactions
between oncogenes and immunity. Moreover, this approach
lends itself to validation using cell-based systems, genetically
engineered mouse models, and human pathology samples. Some
of these concepts are shown in Figure 1.
A Brief Overview of MHC Molecules
Major histocompatibility complex molecules are cell surface
glycoproteins that function to present self- and antigen-derived
TABLE 1 | Alterations of ErbB/HER receptors in human cancer.
Receptor Mutation/Modification Cancer Reference
EGFR/ErbB1/HER1 Overexpression Colorectal carcinoma Moroni et al., 2005
Substitutions G719S, L858R NSCLC Paez et al., 2004
Activating in-frame kinase domain deletions NSCLC Lynch et al., 2004
Overexpression, activating deletions
(truncation), EGFRvIII (801 bp in-frame
deletion of extracellular domain, activating)
Glioblastoma Watanabe et al., 1996; Frederick et al.,
2000; Paff et al., 2014
Overexpression and cytoplasmic
expression
Cutaneous SCC Canueto et al., 2016
Overexpression Head and neck SCC Grandis and Tweardy, 1993
Overexpression Esophageal adenocarcinoma Al-Kasspooles et al., 1993
ErbB2/HER2/NEU Overexpression Breast carcinoma Carey et al., 2006; Howlader et al., 2014
Overexpression Gastric carcinoma Falck and Gullick, 1989; Tanner et al., 2005;
Yano et al., 2006; Hofmann et al., 2008
Insertion, overexpression NSCLC Weiner et al., 1990; Oxnard et al., 2013
Overexpression Bladder carcinoma Neal et al., 1985; Sato et al., 1992; Sauter
et al., 1993
Overexpression Pancreatic carcinoma Yamanaka et al., 1993b; Lei et al., 1995
Overexpression Ovarian carcinoma Meden and Kuhn, 1997
Overexpression Endometrial carcinoma Saffari et al., 1995; Rolitsky et al., 1999
Overexpression Head and neck SCC Beckhardt et al., 1995
Overexpression Esophageal adenocarcinoma Al-Kasspooles et al., 1993
ErbB3/HER3 Substitution V855A (homologous to
EGFR-L858R)
NSCLC Umelo et al., 2016
Overexpression Oral SCC Shintani et al., 1995
ErbB4/HER4 Missense mutations resulting in increased
kinase activity
Melanoma Prickett et al., 2009
Missense/insertions/deletions in kinase
domain
Gastric, breast, lung and colorectal
carcinomas
Soung et al., 2006
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TABLE 2 | Alterations of ErbB/HER ligands in human cancer.
Ligand Mutation/Modification Cancer Reference
Epidermal growth factor (EGF) Overexpression Pancreatic Yamanaka et al., 1993a
Point mutation Gastric Wu et al., 2015
Transforming growth factor-α (TGF-α) Overexpression Prostate Scher et al., 1995
Overexpression Pancreatic Yamanaka et al., 1993a
Overexpression Lung, ovarian, colon Salomon et al., 1995; Rusch et al., 1997
Neuregulin/ Heregulin 1 (Nrg1/Hrg1) Overexpression Breast carcinoma Raj et al., 2001; Slattery et al., 2013
Chromosomal translocation Breast carcinoma Huang et al., 2004
Amphiregulin(AREG) Overexpression Ovarian Niikura et al., 1997
FIGURE 1 | Possible mechanisms through which ErbB/HER oncogenic activating events influence the peptide-MHC (pMHC) repertoire. ErbB/HER
oncogenic events may influence the peptide-MHC repertoire via several possible mechanisms. ErbB/HER oncogenic activation alters the transcriptome of tumor
cells which may include the expression of tumor associated antigens and tumor specific antigens (TSA) such as neoantigens. By altering the transcriptome of tumor
cells, ErbB/HER oncogenic events influence the pool of available proteins available for antigen processing and presentation. In addition, ErbB/HER oncogenic
signaling may influence the expression of components of the antigen processing machinery (APM) including MHCI and MHCII molecules directly or indirectly by
altering the cellular response to cytokines. This will alter the nature and density of the pMHC repertoire. Qualitatively and quantitatively, the nature of the pMHC
repertoire may influence T cell-mediated anti-tumor immune responses.
peptides to cells of the immune system. In humans, MHC
molecules are encoded by human leukocyte antigen (HLA)
genes and these terms are often used interchangeably. MHC
class I (MHCI) molecules consist of two polypeptide chains,
the alpha chain (HLA-A, B, C) and ß2-microglobulin which
are non-covalently associated on the cell surface. The alpha-
1 and alpha-2 domains of the MHC class I molecule form
the peptide binding cleft which binds and presents cytosol-
derived peptides that are 8−11 amino acids in length to
CD8 T lymphocytes (Comber and Philip, 2014). As MHCI
molecules function in concert with CD8 T cells for immune
surveillance against infections and malignancies, these molecules
are expressed on the surface of virtually all nucleated cells and
MHCI expression can be further increased (induced) by type
I and type II interferons (IFNs) as well as other cytokines.
Underscoring their important role in controlling malignancies
and infections is the fact that tumor cells and microbes alike such
as the human immunodeficiency virus (HIV) and Mycobacterium
tuberculosis (Mtb) harbor mechanisms that down-regulate MHCI
expression to facilitate immune escape (Ferris et al., 2006;
Pennini et al., 2006; Choma et al., 2015; Concha-Benavente et al.,
2016).
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MHC class II (MHCII) molecules function to present antigen
to CD4 T lymphocytes generating helper T cell responses that are
critical for effective adaptive immune responses against infection
and cancer (DeSandro et al., 1999; Accolla et al., 2014). Each
MHCII molecule (HLA-DR, DP, DQ) is composed of an alpha
and beta polypeptide chain that non-covalently associate at the
cell surface with one subunit from each chain forming the peptide
binding cleft. MHCII molecules bind peptides of 13−17 amino
acids in length that are generated by proteolysis in lysosomes
and endosomes and are constitutively expressed on the surface
of antigen presenting cells (APCs) such as B cells, macrophages,
and dendritic cells (DCs; Roche and Furuta, 2015).
In order to understand how oncogenic signal transduction
might influence the expression of MHC molecules, it is important
to review some aspects of MHC expression regulation. In
general, though not exclusively, MHC molecules are regulated
transcriptionally and epigenetically (van den Elsen et al.,
2004; Choi et al., 2011; Kobayashi and van den Elsen, 2012).
This regulation is orchestrated at several levels involving
complex interactions between regulatory DNA sequences, within
the MHC locus (such as promoters and enhancers), DNA-
binding transcription factors (TFs) that bind these sequences,
transcriptional co-activators (NLRC5/CITA for MHCI and
CIITA for MHCII) and the formation of complex looping
structures that involve interactions with epigenetic enzymes and
chromatin (Gobin et al., 2001; Meissner et al., 2012). There are
many excellent detailed reviews available on the regulation of
MHCI and MHCII molecules (van den Elsen et al., 1998; van den
Elsen, 2011; Devaiah and Singer, 2013; Neerincx et al., 2013).
When considering interactions between oncogenic signaling
and MHCI expression, two types of expression need to be
considered. Constitutive expression refers to the level of MHCI
molecules expressed under physiologic conditions and varies
between different tissues due in part to differences in epigenetic
marks (Kotekar et al., 2008). In addition to constitutive
expression, increases that occur in response to cytokines are
referred to as inducible expression. Defects in both types of
MHCI expression occur in human cancer (Garrido et al., 2010).
Mechanistically, constitutive MHCI expression is regulated by
distinct regions within MHCI promoters that are binding sites for
TFs such as NFkB, IRF-1, and CREB. The inducible expression
of MHCI molecules occurs in response to cytokines such as
type I and type II interferons (IFNs) and tumor necrosis factor-
alpha (TNF-α) and is mediated through changes in TFs, co-
activators, and other proteins that occur in response to the
inducing cytokine (van den Elsen, 2011). Thus, when considering
interactions between ErbB/HER signaling and MHC expression,
the status of both constitutive and inducible MHCI expression
warrant attention.
In contrast to MHCI, MHCII is expressed constitutively only
on specialized cells of the immune system such as DCs and B
cells. The expression of MHCII is regulated largely via the activity
of the MHCII co-activator (CIITA) which itself is regulated by
distinct promoters that are active in DCs and B cells (named
pI and pIII, respectively). Interestingly, aberrant constitutive
MHCII expression occurs on some tumor cells such as melanoma
(Martins et al., 2007; Degenhardt et al., 2010). Despite this
restricted constitutive expression pattern, MHCII molecules are
inducible by IFN-γ in most cell types; a unique feature of
IFN-γ. The fact that MHCI and MHCII molecules are inducible
by cytokines is highly relevant to ErbB/HER signaling because
as outlined in more detail below, there are functional links
between cytokine signaling and ErbB/HER signaling. Moreover,
ErbB/HER signaling can also influence the expression of the TFs
that bind to the promoters of HLA class I genes such as NFκB
and IRF-1 (Andersen et al., 2008; Shostak and Chariot, 2015).
Thus, ErbB/HER signaling pathways are well poised to alter MHC
expression (positively or negatively) via mechanisms that are not
entirely understood.
MHC Molecules and Cancer
In the setting of cancer, MHC molecules play the pivotal
role of presenting processed tumor antigens to CD4 and CD8
lymphocytes in order to generate a tumor-specific cytotoxic
response (Seliger, 2008b; Hastings, 2013). As tumor antigens
are ultimately derived from self, barriers to the activation of an
antitumor T cell response exist intrinsically as T cells with affinity
for self-antigens are deleted during T cell development. Further,
tumor cells can create an immunosuppressive microenvironment
to suppress anti-tumor T cell responses (Kim et al., 2006). As
mentioned earlier, one mechanism through which tumor cells
evade detection by the immune system is the down regulation
of the surface expression of MHCI molecules. This can occur via
many mechanisms including the genetic loss of the MHC locus,
epigenetic silencing, and many others (Marincola et al., 2000;
Seliger, 2008a,b, 2014; van der Burg et al., 2016). Importantly,
while some of these defects are irreversible, others are not
and in these cases the expression of MHCI molecules can
be corrected or ‘rescued’ by cytokines (such as IFNs) and
medications such as metformin, inhibitors of DNA methylation,
histone deacetylase (HDAC) inhibitors, and other approaches
including targeted therapies as outlined later in this review
(Seliger and Pfizenmaier, 1989; Komatsu and Hayashi, 1998;
Magner et al., 2000; Lopez-Albaitero et al., 2006; Khan et al.,
2008; Han et al., 2011; Lampen and van Hall, 2011; Oliveras-
Ferraros et al., 2012). Many immune-based therapies hinge on the
generation of effector CD4 and/or CD8 T cells. As such, being
able to increase MHCI and/or MHCII levels pharmacologically
on tumor cells would be an attractive complement to CD4/CD8-
based immunotherapy because CD4- and CD8 T cell responses
are functionally influenced by the pMHC density present at the
cell surface. For MHCI, as pMHCI density is increased, T cell
activation becomes more efficient and the inhibition seen in the
setting of an excessively long TCR-pMHCI interaction half-life is
attenuated (Gonzalez et al., 2005). For MHCII, higher pMHCII
density can elicit a more robust CD4 T cell response than the
same pMHCII at a lower density (Vanguri et al., 2013). While it
is less clear if increases in pMHC density can functionally alter
an anti-tumor immune response, increasing pMHC density via
the aforementioned approaches offers another possible avenue to
manipulate interactions between tumor cells and therapeutic T
cells.
In addition to their level of expression, the peptides bound
to MHC molecules play a crucial role in anti-tumor immunity.
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As mentioned previously, the presentation of strongly antigenic
peptides (such as neoantigens derived from mutations) via
MHCI or MHCII can have an enormous impact on clinical
responses to immunotherapies such as those targeting immune
checkpoints (mediated by CTLA-4 signaling and the PD-
1/PD-L1 axis) (Lu and Robbins, 2016; Ward et al., 2016).
With this in mind, it will be crucial to understand how
oncogenic events and anti-cancer therapies influence antigen
processing, antigen presentation, and the pool of antigenic
peptides that can be displayed on the cell surface of tumors
via MHC molecules and detected by anti-tumor CD4- and/or
CD8 T lymphocytes (Chang and Ferrone, 2007; Hastings,
2013).
LINKING ERBB/HER TO THE MHC
Given their canonical roles in cancer biology and immunology,
respectively, it is not surprising that attempts to identify
interactions between the ErbB/HER and MHC molecules goes
back three decades (Schreiber et al., 1984). These initial papers
examined the ability of EGFR ligands to influence MHC
expression. For example, it was found that epidermal growth
factor (EGF) treatment could reduce the binding of KE-2
antibodies (which recognize an epitope on the heavy chain
of HLA class I molecules) to A431 cells; a finding that pre-
dates the seminal paper by Sporn and Roberts (1985) regarding
the autocrine secretion of growth factors such as TGF-α by
cancer cells (Schreiber et al., 1984; Sporn and Roberts, 1985).
In regards to MHCII, links between MHCII expression and
ErbB/HER ligands dates back over two decades where it was
demonstrated that the induction of HLA-DR molecules by
IFN could be attenuated by ErbB/HER ligands EGF and/or
transforming growth factor-α (TGFA) in thyroid epithelial cells
and keratinocytes (Lahat et al., 1992; Mitra and Nickoloff, 1992).
These early studies provided evidence that there were signals
initiated by EGFR activation that had a repressive effect on the
expression of MHCI and MHCII molecules at least in some
cellular contexts.
When considering ErbB/HER−MHC interactions, it is
important to consider the crosstalk that exists between ErbB/HER
receptors and members of the cytokine receptor superfamily
(Kaczmarski and Mufti, 1991; Prenzel et al., 2000). For example,
in response to cytokines such as IFN-γ that induce MHC
expression, ErbB/HER activation can occur via the protease-
dependent release of ErbB/HER ligands (Burova et al., 2007).
As a result, the cellular response to cytokines that induce
MHC molecules involves the activation of ErbB/HER receptors.
This places the EGFR and other members of the ErbB/HER
family, as well as those pathways downstream, in a unique
position to influence the cellular response to cytokines and thus
MHC induction. This becomes even more important when one
considers the dual nature of MHCI regulation described earlier
since malignant cells can harbor defects in constitutive MHCI
expression yet retain their responsiveness to cytokines. In such
a scenario, it is possible that oncogenic ErbB/MHC signaling
would be particularly impactful since MHCI expression on tumor
cells would be effectively dependent on cytokines present in the
tumor microenvironment for MHCI expression yet rendered less
responsive to cytokines due to aberrant ErbB/HER signaling.
ErbB/HER Ligands and MHC Expression
The ligands for ErbB/HER family members are EGF-family
growth factors that include EGF, TGFA, amphiregulin (AREG),
heparin-binding EGF-like growth factor (HBEGF), betacellulin
(BTC), epigen (EPGN), epiregulin (EREG), and four neuregulins
(NRG1-4; are also called heregulins) (Normanno et al., 2003a;
Schneider and Wolf, 2009). These ligands bind ErbB/HER
receptors with varying specificities and induce the formation
of homo- and heterodimers creating a large number of
possible receptor-ligand combinations (Table 3) (Roskoski,
2014). Through these interactions, ErbB/HER ligands initiate
signal transduction via complex signaling networks that lead
to large-scale changes in gene expression (Normanno et al.,
2006). ErbB/HER ligands are widely expressed in epithelial
tissues including those that give rise to the most common
forms of human cancer such as the skin, gut, lungs and the
aerodigestive tract. These ligands exert distinct effects based upon
the receptors they engage and the nature of the downstream
signals they transmit (O-Charoenrat et al., 2002; Zaiss et al.,
2015). For example, by activating different receptors, ligands
induce signals with distinct intensities and durations that in
turn contribute to ligand-specific effects on gene expression
(Nagashima et al., 2007). Moreover, ligands activating the same
ErbB/HER receptor bind with different affinities causing distinct
biological outcomes (Macdonald-Obermann and Pike, 2014).
Transgenic and knockout mouse models have demonstrated
these differences underscoring the fact that these ligands exert
distinct effects even within the same tissue context (Table 4)
(Normanno et al., 2006). In the skin, forced expression of
TGF-α causes papillomas at sites of mechanical irritation,
forced expression of AREG induces psoriatic-like lesions, and
forced expression of betacellulin causes altered hair development
(Vassar and Fuchs, 1991; Dominey et al., 1993; Cook et al., 1997;
Schneider et al., 2008). Knockout studies have also illustrated
the different roles for ErbB/HER ligands within the same tissue
as mice deficient in both EGF and TGF-α expression show
impaired prostate development while mice deficient only in TGF-
α show increased proliferation of prostate tissue compared to
wild-type (Abbott et al., 2003). This suggested that intact TGF-α
signaling is required to control EGF-stimulated proliferation
of prostate tissue. Similar observations were made in the
central and peripheral nervous systems where EGF, TGF-α, and
HBEGF are all expressed. Experiments in mice deficient in TGF-
α demonstrated normal development and functioning of the
peripheral nervous system suggesting EGF and HBEGF signaling
are sufficient and compensate for a lack of TGF-α deficient
signaling (Xian and Zhou, 2004). Despite the above phenotypes,
the impact of ErbB/HER ligands on adaptive immune responses
in these models are incompletely understood in part because
these ligands were initially characterized for their ability to
influence processes such as cell growth and survival. However,
recently there has been a growing appreciation for the immune
functions of ErbB/HER ligands.
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TABLE 3 | ErbB/HER receptors and their cognate ligands.
Ligands ERBB Family Members
EGFR/ ERBB1/ HER1 ERBB2/ HER2/ NEU ERBB3/ HER3 ERBB4/ HER4
EGF + No known ligands
Epigen (EPGN) +
Transforming growth factor-α (TGF-α) +
Amphiregulin (AREG) +
Betacellulin (BTC) + +
Heparin-binding epidermal growth + +
factor-like growth factor (HB-EGF)
Epiregulin (EREG) + +
Neuregulin/Heregulin 1 (Nrg1/Hrg1) + +
Neuregulin/Heregulin 2 (Nrg2/Hrg2) + +
Neuregulin/Heregulin 3 (Nrg3/Hrg3) +
Neuregulin/Heregulin 4 (Nrg4/Hrg4) +
TABLE 4 | Impact of ErbB/HER ligand knockout and overexpression.
Ligand(s) Knockout (KO) Or
overexpression (OE)
Tissues impacted
and/or Phenotype
Reference
TGF-α KO Eyes, hair, and skin Luetteke et al., 1999; Wong,
2003
AREG KO Mammary glands Luetteke et al., 1999
EGF, TGF-α, AREG KO Eyes, hair, skin, mammary Luetteke et al., 1999
EGF OE Infertile, growth retardation,
shortened small intestine
Erwin et al., 1999; Chan and
Wong, 2000; Wong et al., 2000
AREG OE Psoriasis-like dermatitis Cook et al., 1997
TGF-α OE Epithelial hyperplasia,
pancreatic metaplasia, breast
carcinoma
Jhappan et al., 1990; Sandgren
et al., 1990
One important role ErbB/HER ligands in the context
of adaptive immunity was recently uncovered when it was
demonstrated that regulatory T cells (T regs) express the EGFR
and respond to EGFR ligands such as amphiregulin (AREG)
(Zaiss et al., 2013). In addition, a role for AREG in ultraviolet
radiation (UVR)-mediated immunosuppression has recently
been reported (Meulenbroeks et al., 2015). The ability of immune
cells including CD4 and CD8 T cells to produce AREG further
underscores the expanding appreciation for the role of ErbB/HER
ligands in adaptive immune responses including those against
tumors (Zaiss et al., 2006; Kwong et al., 2010; Qi et al., 2012;
Burzyn et al., 2013). Despite these examples, the functional role
of ErbB/HER ligands in shaping anti-tumor immune responses
in vivo is poorly defined though the ability of these ligands to
influence the APM and MHC expression places them in a central
position to do so.
As mentioned above, in the 1980s and 1990s, several groups
found that treatment of cells with ErbB/HER ligands such as
EGF and TGFA repress the expression/induction of MHCI and
MHCII molecules (Schreiber et al., 1984; Lahat et al., 1992;
Mitra and Nickoloff, 1992). More recently, we have also shown
that EGF can repress the induction of MHCII molecules by
IFN-γ (Pollack et al., 2011). Likewise, others have shown similar
effects of ErbB/HER ligands. For example, in their studies on
esophageal and gastric cancer, Mimura et al. demonstrated that
MHCI was repressed by the neuregulin NRG-1-β1 (Mimura
et al., 2013). Likewise, in their studies on prostate cancer, Chen
et al. (2015) showed that EGF could repress MHCI expression.
However, in these and other studies, not all cells respond to
ErbB/HER ligands in the same manner; cells responding to
one ligand may fail to respond to another, and in some cells,
ErbB/HER ligands have no effect on MHC expression (Mimura
et al., 2013; Vantourout et al., 2014; Chen et al., 2015). Such
differences in the responses to ErbB/HER ligands are likely
due to the complex nature of ErbB/HER signaling and MHC
expression. For example, the cellular response to ErbB/HER
ligands depends on ErbB/HER expression patterns and is likely
influenced by the (activation) status of downstream enzymes
(such as RAS and RAF) and other proteins that impact the
TABLE 5 | Examples of ErbB/HER ligands repressing MHC expression.
ERBB/HER Ligand MHC Repressed Reference
EGF MHC class I Schreiber et al., 1984
EGF MHC class II Lahat et al., 1992
EGF/TGFA MHC class II Mitra and Nickoloff, 1992
EGF MHC class II Pollack et al., 2011
NRG-1-b1 MHC class I Mimura et al., 2013
EGF MHC class I Chen et al., 2015
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response to ErbB/HER inhibition (Gazdar, 2009). Moreover, as
mentioned earlier, when considering the impact of ErbB/HER
ligands on MHC expression both constitutive and inducible
MHCI expression warrant investigation as some effects may
require cytokine treatment(s) to be manifest. Table 5 provides a
summary of studies demonstrating repression of MHC molecules
by ErbB/HER ligands (in at least some contexts).
Further complicating the picture, especially as it relates
to ErbB/HER-MHCI interactions, is the fact that ErbB/HER
signaling activates pathways known to have opposing effects on
MHC expression. For example, ErbB/HER signaling can activate
NFκB, IRF-1, and Stat1, known positive regulators of MHC
expression, while at the same time activate the MAPK pathway
which can negatively regulate MHC expression (Figure 2)
(Pedersen et al., 2005; Andersen et al., 2008; van den Elsen,
2011; Mimura et al., 2013; Sapkota et al., 2013; Chen et al.,
2015; Shostak and Chariot, 2015). Therefore, the balance of these
positive and negative regulators of MHC expression induced
in response to ErbB/HER activation may ultimately dictate
their impact on MHC expression. The study by Mimura et al.
highlights this point. In their model, a clear hierarchy existed
as EGF failed to influence MHCI expression, whereas NRG-
1β1 repressed it and both the MAPK and PI3K pathways were
implicated in modulating MHCI expression (Mimura et al.,
2013). Thus, while many questions remain regarding the impact
of ErbB/HER ligands on the APM there is growing evidence
that in some contexts these ligands influence MHC expression.
Moreover, based upon the expression pattern of ErbB/HER
receptors present on a given tumor cell, some ligands may
influence MHC expression whereas others will not. Figure 2
illustrates some of the above concepts.
ErbB/HER Receptors, Inhibitors, and
MHC Expression
The four members of the ErbB/HER family include the EGFR
(also known as ErbB1 and HER1), ErbB2 [also known as HER2
and Neu, ErbB3 (HER3), and ErbB4 (HER4)] (Roskoski, 2014).
Structurally, these receptors contain an extracellular ligand-
binding domain, a transmembrane domain, and a cytoplasmic
domain that contains tyrosine kinase activity (Lemmon et al.,
2014). There are some noteworthy exceptions to the preceding
description. Namely, ErbB2/HER2/neu has no known ligand, and
ErbB3/HER3 has impaired tyrosine kinase activity. ErbB/HER
receptors can signal as homo- or heterodimers creating an array
of combinations that have distinct signaling outputs (Roskoski,
2014). Moreover, hierarchies exist such that the ErbB2/ErbB3
heterodimer is felt to be the most potent ErbB pairing signaling
combination (Pinkas-Kramarski et al., 1996; Tzahar et al., 1996;
Baselga and Swain, 2009). ErbB/HER receptors are widely
expressed on normal and malignant cell types (Salomon et al.,
1995). Genetic knockout of ErbB/HER receptors in mice leads
FIGURE 2 | Potential mechanisms relating ErbB/HER ligands, receptors, and MHC expression. ErbB/HER ligands bind and activate different ErbB/HER
receptors initiating distinct signal transduction pathways and cellular effects. As a result, there may be differences across ligand groups based upon the receptors
and downstream signaling pathways they activate. In addition, even ErbB/HER ligands that bind the same receptors can have distinct impacts on downstream
signaling and as such may have distinct effects on MHC expression. ErbB/HER ligands and receptors activate signaling pathways known to negatively (such as the
MAPK pathway), and positively (such as NFκB and IRF-1), regulate MHC expression via the binding of transcription factors (TFs) to MHC promoters or the promoters
of co-activators such as CIITA. As a result, in any given cellular context, the sum of these opposing effects will likely determine the impact of ErbB/HER activation
and inhibition on MHC expression.
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to alterations in numerous tissues (Table 6). In addition to
their classical roles in regulating cellular proliferation, survival,
angiogenesis, apoptosis, and the cell cycle, these receptors
have recently been implicated in the control of epithelial-
to-mesenchymal transition (EMT) (Chen et al., 2015). Thus,
ErbB/HER family members can regulate a variety of complex
processes including immune responses as outlined below.
Before reviewing the immune effects of ErbB/HER proteins,
it is worth highlighting the fact that these proteins have been
examined from markedly different yet valid perspectives (Seliger
and Kiessling, 2013). From the cancer biology perspective,
ErbB/HER proteins are canonical oncogenic enzymes that
drive tumor cell proliferation/survival/angiogenesis and
metastasis (Hynes and Lane, 2005). This perspective considered
little the immune effects of ErbB/HER proteins yet fueled
enormous efforts to inhibit ErbB/HER expression and/or activity
(Mendelsohn and Baselga, 2000; Normanno et al., 2003a).
Contrasting this view is the tumor immunology perspective
that considers ErbB/HER proteins as bonafide tumor antigens
(Zaks and Rosenberg, 1998; Nistico et al., 1999; Disis et al.,
2000). From this perspective, ErbB/HER-derived peptides
including those derived from activating mutations, such as the
EGFRvIII variant with a mutation in the extracellular domain
of the receptor, have the potential to stimulate an anti-tumor
immune response innately or via vaccination (Li and Wong,
2008; Nedergaard et al., 2012; Paff et al., 2014; Schneble et al.,
2014). Vaccine studies using a 14-amino acid peptide spanning
the mutated extracellular domain of EGFRvIII (CDX-110) fused
to adjuvant have shown durable oncogene-specific antibody
and CD8 T cell responses as well as improved survival in
glioblastoma multiforme patients (Sampson et al., 2008). In
this case, the expression of ErbB/HER proteins on tumor cells
would be required for successful anti-cancer therapy and by
targeting mutations specific to cancer cells these therapies result
in minimal bystander damage of healthy somatic cells expressing
normal ErbB/HER proteins. Other studies incorporate both
perspectives by investigating interactions between oncogenic
ErbB/HER proteins and proteins central to immune responses;
namely MHC molecules.
Attempts to establish links between the expression of
ErbB/HER family members and MHC molecules have been the
subject of study for many years (Nouri et al., 1995; Nistico et al.,
1997; Lollini et al., 1998). Using a forced-expression approach,
Herrmann et al. (2004) demonstrated that the expression of
ErbB2/HER2 was associated with decreases in MHCI and other
components of the APM. Complementing these findings using
siRNA-based approaches, Choudhury et al. (2004) demonstrated
that the loss of ErbB2/HER2 was associated with increases
in MHCI molecules. These studies provided links between
ErbB/HER proteins and MHC expression. The development
of pharmacologic ErbB/HER inhibitors has provided additional
evidence supporting interactions between ErbB/HER proteins
and MHC molecules.
Because MHC molecules govern interactions between tumor
cells and CD4 and CD8 T cells, early studies examined the
effects of ErbB/HER inhibition on MHC expression. In one
early study, no effect of the anti-HER monoclonal antibody
(mAb) trastuzumab on MHC expression was seen though
the treatment did enhance tumor lysis by MHCI-restricted
cytotoxic T lymphocytes (CTLs) (Kono et al., 2004). Our
group explored the impact of EGFR inhibitors on MHCI and
MHCII expression and found that small molecule tyrosine
kinase inhibitors (TKIs) (such as PD168393 and AG1478) as
well as the EGFR blocking antibody cetuximab (alone or with
the ErbB2/HER2/neu blocking antibody trastuzumab) could
enhance the induction of MHCI and MCHII molecules by
IFN-γ (Pollack et al., 2011). In some experimental models, the
addition of either PD168393 or cetuximab alone augmented
MHCI even in the absence of IFN-γ. Subsequent studies
have confirmed that at least under some circumstances
ErbB/HER inhibitors can enhance MHCI and/or MHCII
expression. For example, erlotinib, cetuximab and the pan
ErbB/HER inhibitor dacomitinib increased the induction of
MHCII molecules by IFN-γ in head and neck cancer cell
lines (Kumai et al., 2013, 2015). In their study on non-
small cell lung cancer, Okita et al. (2015) found that gefitinib
upregulated MHCI expression in some cellular contexts.
Moreover, anti-ErbB2/HER2/Neu therapy increased MHCII
TABLE 6 | Tissues altered by genetic knockout of ErbB/HER receptors
Receptor Tissues impacted by genetic
knockout
Reference
ErbB1/HER1/EGFR Epidermis, mammary gland, lung,
pancreas, gastrointestinal tract,
central and peripheral nervous
system, immune system (regulatory
T cells)
Miettinen et al., 1995; Sibilia and
Wagner, 1995; Threadgill et al., 1995;
Sibilia et al., 1998; Wiesen et al., 1999;
Normanno et al., 2003b
ErbB2/HER2/NEU Mammary gland, heart, central
nervous system
Lee et al., 1995; Xie et al., 1997; Jones
and Stern, 1999; Park et al., 2001;
Crone et al., 2002; Leu et al., 2003
ErbB3/HER3 Heart, central and peripheral
nervous system, mammary gland
Erickson et al., 1997; Troyer and Lee,
2001
ErbB4/HER4 Epidermis, mammary gland,
myocardium, central and peripheral
nervous system
Gassmann et al., 1995; Jones et al.,
1999; Golub et al., 2004
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levels in vivo (Mortenson et al., 2013). Further illustrating
relevant functional interactions between ErbB/HER inhibition
and MHC molecules was a study demonstrating that EGFRI
resistance is associated with defects in MHCI expression
(Garrido et al., 2014). The above studies illustrate that under
some contexts, ErbB/HER proteins and inhibitors thereof can
influence the expression of MHC molecules. Table 7 lists studies
reporting increases in MHCI and/or MHCII by ErbB/HER
inhibition.
While the above provide evidence that ErbB/HER activity
impacts MHC expression, it is important to note that just
as was the case for ErbB/HER ligands, not all cells respond
to ErbB/HER inhibition with increases in MHC expression.
We and others have shown that treatment of some cells
with inhibitors of ErbB/HER proteins does not alter MHC
expression (Pollack et al., 2011; Mimura et al., 2013; Okita
et al., 2015). Thus, in some cells, ErbB/HER activity is coupled
to MHC expression, whereas in other cells this is not the
case. While the mechanisms underpinning these interactions
are still being explored, some cells that are unresponsive to
ErbB/HER inhibition respond to inhibitors of downstream
enzymes particularly those inhibiting enzymes in the mitogen-
activated protein kinase (MAPK) pathway as outlined below and
shown in Figure 3.
ErbB/HER Downstream Signaling and
MHC Expression
ErbB/HER proteins are signaling hubs that can initiate signal
transduction via a variety of downstream pathways that include
the RAS/RAF/MAPK pathway, the phosphoinositide-3-kinase
(PI3K) pathway, the phospholipase C-γ (PLC-γ) pathway and
signal transducers and activators of transcription (STATS)
(Pines et al., 2010). Evidence for direct links between enzymes
downstream of ErbB/HER proteins, such as RAS, and the APM
have existed for over twenty years (Seliger et al., 1988, 1996,
1998; Seliger and Pfizenmaier, 1989; Lohmann et al., 1996). In
addition, links between RAS mutations and MHC expression
have been reported in colorectal carcinoma (Atkins et al., 2004).
More recently, inhibitors of the aforementioned pathways have
been exploited to examine interactions between these pathways
and MHC expression. Akin to the development of ErbB/HER
inhibitors, the main paradigm fueling the development these
inhibitors (such as those targeting BRAFV600E and MEK to
inhibit the MAPK pathway and those targeting the PI3K
pathway) centered on their potential to block proliferative
and survival signals rather than their immune effects (Rodon
et al., 2013; Zhao and Adjei, 2014; Sidaway, 2015; Thorpe
et al., 2015). Despite this, there is clear evidence that
inhibition of enzymes downstream of ErbB/HER receptors,
especially the MAPK pathway, alters MHC expression in some
contexts.
Early studies using pre-clinical MEK inhibitors (such as
PD98059) revealed that MEK inhibition augments MHCI and
MHCII expression (as well as CD86, CD80, and CD40) on
and allostimulation by growth factor-dependent DC in the
presence of TNF-α (Yanagawa et al., 2002). Likewise, another
group reported that PD98059 could increase MHCII expression
on monocyte-derived DCs (moDCs) (Aiba et al., 2003). These
studies provided early links between the MAPK pathway and
MHC expression in the context of professional APCs. As
mentioned earlier, similar to tumor cells, microbes such as Mtb
can down-regulate MHC expression to avoid detection by the
immune system. Mechanistically, the MAPK pathway has been
implicated since the down regulation of the MHCII master
regulator CIITA in macrophages by Mtb was mediated by MAPK
signaling and reversed by the MEK inhibitor U0126 (Pennini
et al., 2006). These observations support subsequent studies
demonstrating that MAPK inhibitors influence MHC expression
in the context of cancer.
TABLE 7 | Examples of ErbB/HER inhibitors augmenting MHC expression.
Inhibitor(s) Type of inhibitor Target(s) MHC molecule
increased
Reference
siRNA against ErbB2/HER2 siRNA ErbB2/HER2 MHC class I Choudhury et al., 2004
PD168393 Irreversible kinase
inhibitor
EGFR/ErbB/1/HER1
ErbB2/HER2/neu
MHC class I and
MHC class II
Blair et al., 2007; Pollack
et al., 2011
AG1478 Reversible kinase
inhibitor
EGFR/ErbB/1/HER1 MHC class I and
MHC class II
Zhou and Brattain, 2005;
Pollack et al., 2011
Cetuximab Blocking antibody EGFR/ErbB/1/HER1 MHC class I and
MHC class II
Pollack et al., 2011
Trastuzumab Blocking antibody ErbB2/HER2/neu MHC class I and
MHC class II
Pollack et al., 2011
Erlotinib Reversible kinase
inhibitor
EGFR/ErbB1
ErbB2/HER2/neu
MHC class II Schaefer et al., 2007;
Kumai et al., 2013
Cetuximab Blocking antibody EGFR/ErbB1 MHC class II Kumai et al., 2013
Anti-ErbB2/HER2/Neu Blocking antibody ErbB2/HER2/Neu MHC class II Mortenson et al., 2013
Dacomitinib Irreversible kinase
inhibitor
EGFR/ErbB1/HER1
ErbB/HER2/neu
ErbB4/HER4
MHC class II Kumai et al., 2015
Gefitinib Reversible kinase
inhibitor
EGFR/ErbB1/HER1
ErbB2/HER2/neu
MHC class I Hirata et al., 2005; Okita
et al., 2015
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FIGURE 3 | ErbB/HER downstream signaling pathways may influence the ability of ErbB/HER and other kinase inhibitors to modulate MHC
expression. In settings where the MAPK pathway is actively repressing MHC expression, the location of the activating/oncogenic event (indicated in red) will likely
influence the response to ErbB/HER and/or other kinase inhibitors. (A) In the setting of ErbB/HER ligand overproduction, inhibition of ErbB/HER activity (via an
ErbB/HER inhibitor) and/or enzymes in the MAPK signaling pathway may increase MHC expression. (B) In the setting of ErbB/HER activating mutations and/or
overproduction, an ErbB/HER inhibitor and/or MAPK inhibitor may increase MHC expression. (C) In the setting of an activating RAS mutation, the effect of an
ErbB/HER inhibitor may be null/minimal because MAPK signaling is being driven by activated RAS, whereas a downstream MAPK inhibitor may increase MHC
expression. (D) In the setting of an activating mutation in BRAF, as with an activating RAS mutation, an ErbB/HER inhibitor would not likely change MHC expression
whereas a BRAF inhibitor and/or a MEK inhibitor may increase MHC expression.
Kono and colleagues reported that the expression of
melanoma differentiation antigens (MDAs) increased in the
presence of U0126 and PD98059 (Kono et al., 2006). While
they found no effect on MHC expression, a subsequent study
by Sers et al. (2009) demonstrated that treatment of cells with
the MEK inhibitor U0126 led to increases in MHCI expression.
The FDA approval and clinical use of BRAFV600E and MEK
inhibitors (such as vemurafenib, dabrafenib, and trametinib) have
further underscored the immune effects of MAPK inhibition in
the context of cancer. For example, vemurafenib induced changes
in the expression of melanoma differentiation antigens (MDA),
and the tumor microenvironment in patients including increases
in CD8+ T cell infiltration (Boni et al., 2010; Frederick et al.,
2013). Again, in these studies, no changes in MHC expression
were seen, yet they underscored the potent immunologic effects
induced by disruption of oncogenic MAPK signaling.
Our group looked at the ability of vemurafenib to influence
the induction of MHCI and MHCII molecules by IFN-γ and
IFN-γ2b. We found that in BRAFV600E mutant melanoma
cell lines lacking wild type BRAF the induction of MHCI
and MHCII was enhanced in the presence of vemurafenib
at nanomolar concentrations and that basal levels of MHCI
decreased with the forced expression of BRAFV600E (Sapkota
et al., 2013). Further support identifying the MAPK pathway
(and phospho-ERK in particular) as a dominant regulator of
MHCI expression (in esophageal and gastric cancer) comes
from the study by Mimura and colleagues (Mimura et al.,
2013). More recently, others have reported increases in MHC
expression when oncogenic MAPK signaling is disrupted
especially in the context of cytokine treatment or adoptive
cell therapy (Mimura et al., 2013; Hu-Lieskovan et al., 2015;
Sabbatino et al., 2016; Whipple et al., 2016). Thus, inhibitors
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of MAPK signaling can influence the expression and induction
of MHC molecules in some settings through several possible
mechanisms as outlined below. Table 8 lists examples where
inhibitors of enzymes in the MAPK pathway increase MHC
expression.
One mechanism implicated in mediating MAPK-MHCII
interactions is through the activity of the MHCII co-activator
(and ‘master regulator’) CIITA. CIITA is critical to the generation
of immune responses as it is responsible for regulating the
expression of MHC class II molecules (Choi et al., 2011). CIITA
does not directly bind DNA, but instead regulates transcription
by interacting with TFs and elements of the enhanceosome
complex affecting chromatin remodeling and transcription
initiation (Reith and Boss, 2008; Devaiah and Singer, 2013). The
activity of CIITA is highly regulated through numerous post-
translational modifications including ubiquitination, acetylation,
and phosphorylation (Wu et al., 2009; Morgan et al., 2015). Early
work demonstrated that post-translational phosphorylation of
various serine residues of CIITA, were crucial to its ability to
localize to the nucleus and increase MHC II expression (Greer
et al., 2004). In this study, Greer and colleagues demonstrated
that the loss of these phosphorylation sites was associated with
an increase in the activation of endogenous MHCII genes. This
finding was subsequently confirmed using dominant negative
proteins and the ERK inhibitor PD98059 both of which increased
MHC II induction by CIITA by attenuating ERK activity (Voong
et al., 2008). Thus, while many questions remain, the MAPK
pathway likely impacts MHCII expression in part via changes in
CIITA post-translational modifications.
Compared to MHCII, the mechanisms through which MHCI
is regulated by MAPK signaling is less well defined. Analogous
to CIITA for MHCII, NLRC5/CITA has been shown to be a
key regulator of MHCI expression that has been implicated in
cancer (Meissner et al., 2010; Kobayashi and van den Elsen,
2012; Yoshihama et al., 2016). We have found that vemurafenib
increases in NLRC5/CITA mRNA induction by IFN-γ (Sapkota
et al., 2013). In addition to possible effects on NLRC5/CITA,
others have identified a novel gain-of-function activity of
BRAFV600E that directly targets MHCI protein for degradation
(Bradley et al., 2015). This study underscores the intimate links
that exist between oncogenes and MHC expression.
INCORPORATING INFORMATICS TO
HELP UNDERSTAND ERBB/HER – MHC
INTERACTIONS
Given the complex nature of oncogenic signaling and the
regulation of immune responses, many complementary
approaches need to be used in order to fully understand
how ErbB/HER oncogenic signal transduction influences the
expression of MHC molecules and the APM. These will likely
include biochemical studies, cell-based studies, murine models,
and a detailed analysis of human samples. While bioinformatics
approaches are integral to all of the aforementioned models,
they are particularly useful in the setting of large tumor tissue
databases (Cooper et al., 2015; Li et al., 2015). Having databases
containing genomic, transcriptomic, and proteomic information
provides an invaluable opportunity to characterize relationships
between genomic events and those relevant to immunity in the
context of human cancer (Rutledge et al., 2013; Saba et al., 2015).
An example relevant to MHCI expression and regulation in
human cancer is outlined below.
NLRC5/CITA was known to be an important regulator of
MHCI molecules, yet until recently, its role in the setting of
human cancer was poorly defined. In a recently published study
by Yoshihama and colleagues, our understanding of the role of
NLRC5 in human cancer was greatly expanded (Yoshihama et al.,
2016). The authors in this study included bioinformatics-based
approaches to assess the expression pattern of NLRC5/CITA
and MHCI in human cancer thereby providing a much better
understanding of how NLRC5/CITA expression correlates with
other immune parameters in the setting of human tumors.
Moreover, these authors used this approach to determine that
expression of NLRC5/CITA correlated with survival in several
cancer types including melanoma, rectal cancer, bladder cancer,
uterine cancer, cervical cancer and head/neck cancer. This study
illustrates how genetic information from human tumor databases
can be combined with bioinformatics to generate clinically
relevant information. A brief description of some of these
resources and approaches are reviewed in the next paragraph.
A number of public bioinformatics resources exist to
investigate the relationship between immune parameters,
oncogenic driver mutations and signaling network activation.
TABLE 8 | Inhibition of enzymes in the MAPK pathway enhancing MHC expression
Inhibitor(s) Enzyme inhibited MHC molecule increased Reference
PD98059 MEK1MEK2 MHC class I and MHC class II Yanagawa et al., 2002
PD98059 MEK1MEK2 MHC class II Aiba et al., 2003
U0126 MEK1MEK2 MHC class I Sers et al., 2009
Vemurafenib BRAFV600E MHC class I and MHC class II Sapkota et al., 2013
PD98059 MEK1MEK2 MHC class I Mimura et al., 2013
Dabrafenib BRAFV600E MHC class I Hu-Lieskovan et al., 2015
Trametinib MEK1MEK2 MHC class I Hu-Lieskovan et al., 2015
Vemurafenib BRAFV600E MHC class I Sabbatino et al., 2016
Vemurafenib BRAFV600E MHC class I Whipple et al., 2016
U0126 MEK1MEK2 MHC class I Whipple et al., 2016
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The Cancer Genome Atlas1 is a public data resource of the
National Cancer Institute that has produced comprehensive
genomic, epigenomic, transcriptomic, and proteomic profiles
of over 11,000 patients with 33 distinct cancer types. The
data generated by TCGA is readily accessible via a number
of stand-alone public resources that facilitate exploration of
mutational spectra and copy number events, gene expression and
their relationship to clinical outcomes including the cBioPortal2,
the Broad Institute Tumor Portal3, and the Cancer Regulome
Explorer4(Cerami et al., 2012; Gao et al., 2013; Lawrence et al.,
2014). The use of these resources and others will provide
important avenues to examine interactions between ErbB/HER
ligands, receptors, and the APM to understand interactions
between these important oncogenes and adaptive immune
responses in a more comprehensive manner.
CONCLUSION
In summary, functional links between ErbB/HER ligands,
receptors, and MHC molecules demonstrates the intimate
connections that can exist between oncogenes and genes that
regulate antigen processing and presentation. The clinical use
of ErbB/HER inhibitors provides a unique opportunity to
1 cancergenome.nih.gov
2 http://www.cbioportal.org/
3 http://www.tumorportal.org/
4 http://explorer.cancerregulome.org/
define these relationships in more depth and to gain insight
into how signaling pathways defined for their role in cancer
influence fundamental immunologic processes. This information
will enhance our ability to use targeted therapies with more
insight and more rationally combine them with immune-based
therapies.
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